Trastuzumab Deruxtecan Prolongs OS in Second-Line Treatment for Patients with HER2-positive Metastatic Gastric or GEJ Adenocarcinoma By Ogkologos - July 2, 2025 398 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DESTINY-Gastric04 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR How Music Can Help You Cope During Cancer: An Expert Perspective October 5, 2021 EMA Recommends Extension of Indications for Talazoparib November 27, 2023 Toddler Hailed A Hero After He Saved His Family From Fire... January 28, 2022 EMA Recommends Extension of Therapeutic Indications for Niraparib / Abiraterone Acetate February 20, 2026 Load more HOT NEWS Investing in volunteers since 2002: The tale of time ESMO Immuno-Oncology Congress 2021, Geneva, Switzerland, 8-11 December TACE-Based Treatment Combinations Effective Against Intermediate-Stage Liver Cancer Predictive Performance of DNA Methylation-based Test in Combination with HPV16/18 Genotyping...
